118 related articles for article (PubMed ID: 38280480)
1. Direct interaction of platelet with tumor cell aggravates hepatocellular carcinoma metastasis by activating TLR4/ADAM10/CX3CL1 axis.
Gao JH; He AD; Liu LM; Zhou YJ; Guo YW; Lu M; Zeng XB; Gong X; Lu YJ; Liang HF; Zhang BX; Ma R; Zhang RY; Ming ZY
Cancer Lett; 2024 Mar; 585():216674. PubMed ID: 38280480
[TBL] [Abstract][Full Text] [Related]
2. TLR4-mediated galectin-1 production triggers epithelial-mesenchymal transition in colon cancer cells through ADAM10- and ADAM17-associated lactate production.
Park GB; Kim D
Mol Cell Biochem; 2017 Jan; 425(1-2):191-202. PubMed ID: 27837433
[TBL] [Abstract][Full Text] [Related]
3. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.
Xu Y; Lai Y; Cao L; Li Y; Chen G; Chen L; Weng H; Chen T; Wang L; Ye Y
RNA Biol; 2021 Oct; 18(10):1408-1423. PubMed ID: 33206588
[TBL] [Abstract][Full Text] [Related]
4. The miR-561-5p/CX
Chen EB; Zhou ZJ; Xiao K; Zhu GQ; Yang Y; Wang B; Zhou SL; Chen Q; Yin D; Wang Z; Shi YH; Gao DM; Chen J; Zhao Y; Wu WZ; Fan J; Zhou J; Dai Z
Theranostics; 2019; 9(16):4779-4794. PubMed ID: 31367257
[TBL] [Abstract][Full Text] [Related]
5. miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma.
Liu Y; Zhang W; Liu S; Liu K; Ji B; Wang Y
Oncol Rep; 2017 Mar; 37(3):1857-1864. PubMed ID: 28184920
[TBL] [Abstract][Full Text] [Related]
6. ADAM17-regulated CX3CL1 expression produced by bone marrow endothelial cells promotes spinal metastasis from hepatocellular carcinoma.
Sun C; Hu A; Wang S; Tian B; Jiang L; Liang Y; Wang H; Dong J
Int J Oncol; 2020 Jul; 57(1):249-263. PubMed ID: 32319605
[TBL] [Abstract][Full Text] [Related]
7. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
8. Platelets are recruited to hepatocellular carcinoma tissues in a CX3CL1-CX3CR1 dependent manner and induce tumour cell apoptosis.
Miao S; Lu M; Liu Y; Shu D; Zhu Y; Song W; Ma Y; Ma R; Zhang B; Fang C; Ming ZY
Mol Oncol; 2020 Oct; 14(10):2546-2559. PubMed ID: 32799418
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma.
Wu G; Zheng K; Xia S; Wang Y; Meng X; Qin X; Cheng Y
J Exp Clin Cancer Res; 2016 Jun; 35(1):89. PubMed ID: 27259866
[TBL] [Abstract][Full Text] [Related]
10. HAX-1 promotes the migration and invasion of hepatocellular carcinoma cells through the induction of epithelial-mesenchymal transition via the NF-κB pathway.
Hu YL; Feng Y; Ma P; Wang F; Huang H; Guo YB; Li P; Mao QS; Xue WJ
Exp Cell Res; 2019 Aug; 381(1):66-76. PubMed ID: 31047882
[TBL] [Abstract][Full Text] [Related]
11. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma.
Liu WT; Jing YY; Yu GF; Han ZP; Yu DD; Fan QM; Ye F; Li R; Gao L; Zhao QD; Wu MC; Wei LX
Cancer Lett; 2015 Mar; 358(2):136-143. PubMed ID: 25511737
[TBL] [Abstract][Full Text] [Related]
12. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
Liu S; Zhang W; Liu K; Ji B; Wang G
Mol Med Rep; 2015 Jan; 11(1):597-602. PubMed ID: 25323956
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.
Liu S; Zhang W; Liu K; Wang Y; Ji B; Liu Y
Oncol Rep; 2014 Dec; 32(6):2501-10. PubMed ID: 25242535
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding LINC01551 promotes hepatocellular carcinoma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of microRNA-122-5p to regulate ADAM10 expression.
Gao J; Yin X; Yu X; Dai C; Zhou F
J Cell Biochem; 2019 Oct; 120(10):16393-16407. PubMed ID: 31270840
[TBL] [Abstract][Full Text] [Related]
15. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer.
Mueller AC; Piper M; Goodspeed A; Bhuvane S; Williams JS; Bhatia S; Phan AV; Van Court B; Zolman KL; Peña B; Oweida AJ; Zakem S; Meguid C; Knitz MW; Darragh L; Bickett TE; Gadwa J; Mestroni L; Taylor MRG; Jordan KR; Dempsey P; Lucia MS; McCarter MD; Del Chiaro M; Messersmith WA; Schulick RD; Goodman KA; Gough MJ; Greene CS; Costello JC; Neto AG; Lagares D; Hansen KC; Van Bokhoven A; Karam SD
Cancer Res; 2021 Jun; 81(12):3255-3269. PubMed ID: 33526513
[TBL] [Abstract][Full Text] [Related]
16. M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway.
Yao RR; Li JH; Zhang R; Chen RX; Wang YH
World J Surg Oncol; 2018 Jan; 16(1):9. PubMed ID: 29338742
[TBL] [Abstract][Full Text] [Related]
17. CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways.
Han J; Fu R; Chen C; Cheng X; Guo T; Huangfu L; Li X; Du H; Xing X; Ji J
Int J Biol Sci; 2021; 17(11):2841-2852. PubMed ID: 34345211
[TBL] [Abstract][Full Text] [Related]
18. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
19. Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes.
O'Sullivan SA; Gasparini F; Mir AK; Dev KK
J Neuroinflammation; 2016 Aug; 13(1):189. PubMed ID: 27549131
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy.
Abu El-Asrar AM; Nawaz MI; Ahmad A; De Zutter A; Siddiquei MM; Blanter M; Allegaert E; Gikandi PW; De Hertogh G; Van Damme J; Opdenakker G; Struyf S
Front Immunol; 2020; 11():601639. PubMed ID: 33552057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
